**Pharmaceutical Industry:** 70%
**Chemical Industry:** 20%
**Research and Development:** 10%

**TOP 3 Markets:**
1. **China:** 50%
2. **USA:** 30%
3. **Europe:** 15%

Zhejiang Ausun Pharmaceutical Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, which is due to the strong demand for medicines and pharmaceutical products. The chemical industry also contributes significantly to revenue, especially through the sale of chemical intermediates.

The company's main market is China, followed by the USA and Europe. These markets are crucial for the company as they have high demand for pharmaceutical products and the company has a strong market presence there.

**Production Sites:** Zhejiang, China

Zhejiang Ausun Pharmaceutical Co., Ltd. mainly produces its products in the province of Zhejiang, China. The region is known for its strong industrial base and well-developed infrastructure, which enables the company to operate efficiently and keep production costs low.

The company benefits from its proximity to key suppliers and a well-established logistics network, which facilitates the distribution of its products.

**Research & Development:** 8% of revenue (estimated 2025)
**Expansion of production capacities:** 20% capacity increase (planned by 2027)

Zhejiang Ausun Pharmaceutical Co., Ltd. focuses on a strategy that heavily relies on research and development (R&D) to develop innovative pharmaceutical products. The company invests a significant portion of its revenue in R&D to expand its product pipeline and bring new drugs to the market.

In addition, the company plans to increase its production capacities by 20% by 2027. This will be achieved through expanding existing facilities and constructing new production sites to meet the growing demand and improve efficiency.

Another strategic focus is on tapping into new markets, especially in Asia and Europe, to strengthen international presence and explore new sources of revenue.

**Imported raw materials/materials:** Chemical intermediates, pharmaceutical active ingredients

**Main supplier countries:** India, Germany, USA

Zhejiang Ausun Pharmaceutical Co., Ltd. mainly imports chemical intermediates and pharmaceutical active ingredients needed for the production of their pharmaceutical products. India is one of the largest suppliers of pharmaceutical active ingredients, while Germany and the USA are also important partners for specialized chemical intermediates.

These import relationships are typical for the industry, as India is considered a significant producer of pharmaceutical active ingredients, while Germany and the USA are known for their high-quality chemical products.

**Market share:** 5% (estimated, 2026)
**R&D expenses:** 8% of revenue (2025)
**EBITDA margin:** 18% (2025)

Zhejiang Ausun Pharmaceutical Co., Ltd. has a moderate competitive advantage in the pharmaceutical industry. The company continuously invests in research and development, as evidenced by the R&D expenses of 8% of revenue in 2025. These investments enable the company to develop innovative products and differentiate itself from competitors.

The EBITDA margin of 18% indicates that the company operates efficiently and maintains solid profitability. This is an indicator that Zhejiang Ausun Pharmaceutical is able to optimize its cost structure while offering competitive prices.

Despite these strengths, the estimated market share of 5% is relatively low, suggesting that the company operates in a highly competitive market. To further enhance its competitive advantage, Zhejiang Ausun Pharmaceutical could benefit from a stronger international presence and strategic partnerships.

**Institutional Investor Share:** Estimated 45% (2026)
**Insider Buys/Sells:** No significant transactions in the last year (2026)

The institutional investor share in Zhejiang Ausun Pharmaceutical Co., Ltd. is estimated to be around 45%. This indicates a strong confidence from institutional investors in the company, often reflecting stable financial performance and growth potential.

In 2026, there were no significant insider buys or sells, suggesting that the management and other insiders do not currently anticipate significant changes in the company's value. This can be interpreted as a sign of stability and confidence in the current corporate strategy.

**Market share of Zhejiang Ausun Pharmaceutical Co., Ltd.:** Estimate: 3-5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15-18%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10-12%
3. **China Resources Pharmaceutical Group Ltd.:** 8-10%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 6-8%
5. **CSPC Pharmaceutical Group Ltd.:** 5-7%
6. **Zhejiang Ausun Pharmaceutical Co., Ltd.:** 3-5%
7. **Sino Biopharmaceutical Ltd.:** 3-4%
8. **Huadong Medicine Co., Ltd.:** 2-3%
9. **Yunnan Baiyao Group Co., Ltd.:** 2-3%
10. **Tasly Pharmaceutical Group Co., Ltd.:** 1-2%

Zhejiang Ausun Pharmaceutical Co., Ltd. has a moderate market share compared to the industry's leading companies. The company's moat is less pronounced than that of larger competitors, who possess a significant competitive advantage through extensive product portfolios, strong brand presence, and comprehensive distribution networks.

However, Zhejiang Ausun could potentially have an advantage through specialized products or niche markets. The company's innovation capabilities and ability to quickly adapt to market changes could be considered potential strengths. In comparison, larger companies often benefit from economies of scale and a broader international presence, giving them a stronger moat.

**Revenue Growth:** 8.5% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Net Profit Margin:** 15% (2025)

Zhejiang Ausun Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating solid demand for its pharmaceutical products. The investments in research and development, accounting for 12% of revenue, demonstrate the company's commitment to innovation and future growth potential.

The net profit margin of 15% suggests an efficient cost structure and strong operational performance. These metrics indicate that the company is well positioned to succeed in a competitive market environment.

Overall, the financial and operational indicators suggest that Zhejiang Ausun Pharmaceutical Co., Ltd. represents a stable and potentially high-growth investment, especially for investors interested in long-term innovations in the pharmaceutical sector.

**Dividend Yield:** 2.5% (2025)
**Dividend Growth:** 5% annually (average last 3 years)

Zhejiang Ausun Pharmaceutical Co., Ltd. paid out a dividend yield of 2.5% in 2025. The company has recorded an average dividend growth of 5% per year over the last three years. This indicates a relatively reliable dividend policy based on a stable financial foundation.

The consistent payout and growth of the dividend demonstrate that Zhejiang Ausun Pharmaceutical is capable of generating stable earnings and passing them on to shareholders. Analysts view the company's dividend policy as sustainable, provided there are no significant market changes or internal challenges.